35.07
+1.07(+3.15%)
Currency In USD
| Previous Close | 34 |
| Open | 34.14 |
| Day High | 35.15 |
| Day Low | 34.05 |
| 52-Week High | 35.77 |
| 52-Week Low | 12.21 |
| Volume | 189,602 |
| Average Volume | 526,126 |
| Market Cap | 981.82M |
| PE | -7.99 |
| EPS | -4.39 |
| Moving Average 50 Days | 25.52 |
| Moving Average 200 Days | 21.49 |
| Change | 1.07 |
If you invested $1000 in AnaptysBio, Inc. (ANAB) since IPO date, it would be worth $2,062.94 as of October 26, 2025 at a share price of $35.07. Whereas If you bought $1000 worth of AnaptysBio, Inc. (ANAB) shares 5 years ago, it would be worth $1,264.7 as of October 26, 2025 at a share price of $35.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
GlobeNewswire Inc.
Oct 13, 2025 1:15 PM GMT
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab,
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
GlobeNewswire Inc.
Sep 29, 2025 8:05 PM GMT
Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
GlobeNewswire Inc.
Sep 29, 2025 8:05 PM GMT
SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD1